Clinical Trials Update from NCI, September 2022

National Cancer Institute banner

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 
Clinical Trials
Updates from the National Cancer Institute
 
Clinical Trials News
 
Child with cancer and mother  

Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug Hawkins


Dr. Doug Hawkins, chair of the NCI-funded Children’s Oncology Group (COG), discusses advances in treating children with cancer, COG’s role in conducting clinical trials, and efforts like the Childhood Cancer Data Initiative and Molecular Characterization Initiative.

 
Structure of an antibody-drug conjugate  

First Targeted Therapy Approved for HER2-Mutant Lung Cancer


On August 11, the Food and Drug Administration gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer that has a specific mutation in the HER2 gene. The approval was mainly based on the results of the phase 2 DESTINY-Lung02 clinical trial.

 
Neuroblastoma under microscope  

Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma


Researchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.

 
 
Clinical Trials Information for Patients and Caregivers
 

Randomization and Bias in Cancer Clinical Trials


In some phase 2 and all phase 3 clinical trials, patients are assigned to groups that receive different treatments. The process of assigning patients to these groups by chance is called randomization. This page and the resources below explain why and how patients are randomized in clinical trials.

 

Infographic: Clinical Trial Randomization


View this infographic to learn more about how people participating in clinical trials are randomly assigned, or randomized, to different treatment groups.

 

Video: Randomization in Clinical Trials


Learn how researchers randomly assign clinical trial participants to different treatment groups in order to prevent bias in the results.

 
Search for a clinical trial  

Find NCI-Supported Clinical Trials


Use our search form to find a clinical trial or other research study that may be right for you or a loved one.

 
NCI-Supported Clinical Trials That Are Recruiting Patients 
 

Testing Drug Combination for Cancer in the Abdominal Lining


This phase 2 trial will test the combined use of paclitaxel with the oral drug nilotinib for people with tumors in the lining of their abdomen that have spread from ovarian, colorectal, or appendix cancer (called peritoneal carcinomatosis). Doctors want to see if giving the drugs together shrinks tumors enough for patients to have surgery.

 

Internet-Based Pain Management for Cancer Survivors


This clinical study will test whether people who have had cancer treatment get more pain relief by adding an internet-based program to usual care or from usual pain management care by itself. Study participants will be randomly assigned to the internet program or standard pain management. After 6 months, researchers will assess pain scores, and will give those receiving only standard care access to the internet-based program.

 

Immunotherapy Added to Chemotherapy and Radiation for Bladder Cancer


This phase 3 trial will test how well chemotherapy and radiation therapy work with or without the immunotherapy drug atezolizumab (Tecentriq) for people with localized muscle-invasive bladder cancer. Doctors want to see if adding atezolizumab to standard treatment improves bladder preservation, overall survival, and duration of complete responses.